Fig. 7.
Antibody protection of CHIKV- and MAYV-induced musculoskeletal disease in vivo. (A) CHIKV- and MAYV-induced joint swelling in mAb-treated mice. The 4-wk-old C57BL/6J mice were administered 200 µg (10 mg/kg) DC2.M16, DC2.M357, or isotype control mAb by intraperitoneal route 1 d before subcutaneous inoculation of either 103 FFU CHIKV-LR2006-OPY1 or MAYV-BeH407 in the footpad. Swelling was measured in the ipsilateral ankle using digital calipers over 14 d. Two independent experiments were performed, with n = 10 mice per antibody for each group (two-way ANOVA with Tukey’s posttest). CHIKV-LR2006-OPY1 (B) and MAYV-BeH407 (C) viral titers in ankle, calf muscle, spleen, and draining lymph node (DLN) were determined 3-d postinoculation. Viral RNA levels were measured by qRT-PCR and compared to a viral RNA standard curve, generated from titered viral stock to determine FFU equivalents. Two independent experiments were performed, with n = 6 mice per antibody for each group (one-way ANOVA with Dunnett’s posttest). *P < 0.05; **P < 0.01; ***P < 0.001, and ****P < 0.0001, compared to isotype control.